New direct oral anticoagulants (NOAC) – solutions to potential problems with coagulation assessment
Authors:
Kvasnička Jan; Malíková Ivana
Authors‘ workplace:
Trombotické centrum ÚLBLD Všeobecné fakultní nemocnice a 1. lékařské fakulty Univerzity Karlovy, Praha
Published in:
Anest. intenziv. Med., 25, 2014, č. 5, s. 367-372
Category:
Intesive Care Medicine - Special Article
Overview
An overview of the options for laboratory monitoring of the new oral anticoagulants (the direct Xa inhibitors rivaroxaban and apixaban and the direct thrombin inhibitor dabigatran), and selection of appropriate coagulation tests that can be used in clinical practice are presented.
Keywords:
laboratory tests – rivaroxaban – apixaban – dabigatran – emergency medicine
Sources
1. Kvasnička, J., Hájková, J., Bobčíková, P. et al. Prevalence polymorfismů CYP2C9 a VKORC1 v České republice a zamyšlení nad výhledy antikolagulační léčby warfarinem. Cor et Vasa, 2011, 53, s. 522–526.
2. Souhrn údajů o přípravku Xarelto [online]. [cit. 2013-12-18]. Dostupný na www: http://www.emea.europa.eu/docs/cs_CZ/document_library/EPAR_Product_Information/human/000944/WC500057108.pdf.
3. Souhrn údajů o přípravku Eliquis. [online]. [cit. 2013-12-18]. Dostupný na www: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_Product_Information/human/002148/WC500107728.pdf.
4. Souhrn údajů o přípravku Pradaxa. [online]. [cit. 2013-12-18]. Dostupný na www: http://www.emea.europa.eu/docs/cs_CZ/document_library/EPAR_Product_Information/human/000829/WC500041059.pdf.
5. Ageno, W., Crowther, M., Baglin, T. et al. Selection and assessment of patients treated with the novel oral antikoagulant drugs: a recomendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis, 2012, 11, s. 177–179.
6. Kozek-Langenecker, S. A. , Afshari, A., Albaladejo, P. et al. Management of severe perioperative bleeding. European Journal of Anaesthesiology, 2013, 30, s. 270–382.
7. van Veen, J. J., Smith, J., Kitchen, S., Makris, M. Normal prothrombin time in the presence of therapeutic levels of rivaroxaban. British Journal of Haematology, 2013, 160, s. 859–861.
8. Tripodi, A., Chantarangkul, V., Guinet, C., Samama, M. M. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients. results of an in vitro study. Journal of Thrombosis and Haemostasis, 2011, 9, s. 226–228.
9. Tsakiris, D. A., Alberio, L. A. et al. Quantifizierung von Rivaroxaban und Beeinflussung von Gerinnungstests bei Patienten mit Rivaroxaban (Xarelto®) [online]. [cit. 2013-12-18]. Dostupný na www: http://www.sgh-ssh.ch/upload/File/2012_11.10._Rivaroxaban_D.pdf.
10. Baglin, T., Hillarp, A., Tripodi, A. et al. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis, 2013, 12, s. 756–760.
11. Čihák, R., Haman, L., Táborský, M. Praktická doporučení European Heart Rhythm Association pro použití nových perorálních antikoagulancií u pacientů s nevalvulární fibrilací síní. Cor et Vasa, 2014, 56, s. 42–56.
Labels
Anaesthesiology, Resuscitation and Inten Intensive Care MedicineArticle was published in
Anaesthesiology and Intensive Care Medicine
2014 Issue 5
Most read in this issue
- New direct oral anticoagulants (NOAC) – solutions to potential problems with coagulation assessment
- Theophylline poisoning – case report and review of literature
- Recommendation for analgesia and sedation of adult patients in intensive care
- Triage strategy for urgent management of cardiac tamponade